IS5852A - Lyfjamiðlar til meðhöndlunar á parkinsonsveiki ADHD og smákirtilsæxlum - Google Patents

Lyfjamiðlar til meðhöndlunar á parkinsonsveiki ADHD og smákirtilsæxlum

Info

Publication number
IS5852A
IS5852A IS5852A IS5852A IS5852A IS 5852 A IS5852 A IS 5852A IS 5852 A IS5852 A IS 5852A IS 5852 A IS5852 A IS 5852A IS 5852 A IS5852 A IS 5852A
Authority
IS
Iceland
Prior art keywords
smallpox
medications
parkinson
treatment
adhd
Prior art date
Application number
IS5852A
Other languages
English (en)
Inventor
Rose Jackson Elisa
Mclean Stafford
Howard Zorn Stevin
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS5852A publication Critical patent/IS5852A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS5852A 1998-09-21 2001-02-20 Lyfjamiðlar til meðhöndlunar á parkinsonsveiki ADHD og smákirtilsæxlum IS5852A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10119198P 1998-09-21 1998-09-21
US10386898P 1998-10-12 1998-10-12
PCT/IB1999/001503 WO2000016777A1 (en) 1998-09-21 1999-09-03 Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas

Publications (1)

Publication Number Publication Date
IS5852A true IS5852A (is) 2001-02-20

Family

ID=26798000

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5852A IS5852A (is) 1998-09-21 2001-02-20 Lyfjamiðlar til meðhöndlunar á parkinsonsveiki ADHD og smákirtilsæxlum

Country Status (38)

Country Link
US (2) US6300329B1 (is)
EP (1) EP1115402A1 (is)
JP (1) JP2002526448A (is)
KR (3) KR20030088512A (is)
CN (1) CN1319013A (is)
AP (1) AP1456A (is)
AR (1) AR029739A1 (is)
AU (1) AU760230B2 (is)
BG (1) BG105445A (is)
BR (1) BR9913975A (is)
CA (1) CA2344670A1 (is)
CO (1) CO5140075A1 (is)
CZ (1) CZ20011006A3 (is)
DZ (1) DZ2894A1 (is)
EA (2) EA200301063A1 (is)
EE (1) EE200100179A (is)
GE (1) GEP20033081B (is)
GT (1) GT199900154A (is)
HN (1) HN1999000146A (is)
HR (1) HRP20010209A2 (is)
HU (1) HUP0103691A3 (is)
ID (1) ID28028A (is)
IL (2) IL141507A0 (is)
IS (1) IS5852A (is)
MA (1) MA26690A1 (is)
MY (1) MY127939A (is)
NO (1) NO20011409L (is)
NZ (1) NZ509855A (is)
OA (1) OA11653A (is)
PA (1) PA8482001A1 (is)
PE (1) PE20001084A1 (is)
PL (1) PL346904A1 (is)
SK (1) SK3592001A3 (is)
TN (1) TNSN99177A1 (is)
TR (2) TR200101357T2 (is)
TW (1) TW518225B (is)
WO (1) WO2000016777A1 (is)
YU (1) YU21701A (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
GB0027020D0 (en) 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
WO2002102988A2 (en) * 2001-06-18 2002-12-27 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5ht-1a agonists
US20030036555A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Kg Pramipexole for the treatment of ADHD
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US7737128B2 (en) * 2004-06-10 2010-06-15 The Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
WO2006020703A1 (en) * 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
AR055424A1 (es) 2005-09-12 2007-08-22 Wyeth Corp Formulacion de liberacion sostenida y usos de la misma
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
WO2016186968A1 (en) 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX19222A (es) * 1989-01-23 1993-12-01 Pfizer Agentes ansioliticos bis-aza-biciclicos
WO1992000075A1 (en) * 1990-06-29 1992-01-09 Pfizer Inc. Pyridopyrazine derivatives for treating substance abuse and addiction
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
JP2860604B2 (ja) * 1994-06-14 1999-02-24 ファイザー インク． 中枢ドーパミン作動活性を有するベンズイミダゾロン誘導体
US5877183A (en) * 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

Also Published As

Publication number Publication date
GT199900154A (es) 2001-03-06
US20010034347A1 (en) 2001-10-25
EA200301063A1 (ru) 2004-12-30
CA2344670A1 (en) 2000-03-30
AR029739A1 (es) 2003-07-16
EA200100204A1 (ru) 2001-08-27
HRP20010209A2 (en) 2002-04-30
CZ20011006A3 (cs) 2001-09-12
IL141507A0 (en) 2002-03-10
JP2002526448A (ja) 2002-08-20
US6608064B2 (en) 2003-08-19
NO20011409D0 (no) 2001-03-20
KR100468340B1 (ko) 2005-01-27
ID28028A (id) 2001-05-03
HUP0103691A2 (hu) 2002-02-28
MA26690A1 (fr) 2004-12-20
YU21701A (sh) 2004-07-15
PA8482001A1 (es) 2000-05-24
TNSN99177A1 (fr) 2005-11-10
CN1319013A (zh) 2001-10-24
TW518225B (en) 2003-01-21
HN1999000146A (es) 2000-11-11
SK3592001A3 (en) 2001-12-03
IL164839A0 (en) 2005-12-18
BG105445A (en) 2001-12-29
WO2000016777A1 (en) 2000-03-30
CO5140075A1 (es) 2002-03-22
NO20011409L (no) 2001-03-28
KR20010075222A (ko) 2001-08-09
US6300329B1 (en) 2001-10-09
BR9913975A (pt) 2001-06-19
EE200100179A (et) 2002-10-15
NZ509855A (en) 2003-04-29
AU5383199A (en) 2000-04-10
EP1115402A1 (en) 2001-07-18
KR20030088512A (ko) 2003-11-19
OA11653A (en) 2004-12-08
AU760230B2 (en) 2003-05-08
GEP20033081B (en) 2003-10-27
HUP0103691A3 (en) 2003-01-28
PL346904A1 (en) 2002-03-11
DZ2894A1 (fr) 2003-12-15
AP2001002102A0 (en) 2001-03-31
KR20040054752A (ko) 2004-06-25
MY127939A (en) 2007-01-31
PE20001084A1 (es) 2000-10-18
AP1456A (en) 2005-09-30
TR200101357T2 (tr) 2001-08-21
TR200402083T2 (tr) 2004-10-21

Similar Documents

Publication Publication Date Title
NO20011409L (no) Farmasöytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
NO20004098L (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
NO994613D0 (no) Fremgangsmaate og preparat til behandling av sövn-apne
IS5500A (is) Lyfjablöndur til öftrunar og meðferðar mýlildi ogtengdum sjúkdómum
FI20000720L (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
EP1015578A4 (en) THERAPEUTIC MOLECULES
NO20063000L (no) Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav.
NO983576D0 (no) Brönnbehandlingsfluider og fremgangsmåter
DK1223997T3 (da) Medicinsk infusionssæt
FI964284A7 (fi) Apolipoproteiini E:n polymorfismi ja Alzheimerin taudin hoito
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
NO20005179D0 (no) Medikament behandling
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
EP1044211A4 (en) 36 HUMAN SECRETED PROTEINS
DK91793D0 (da) Fremgangsmaade til overfladebehandling, midler til udoevelse og anvendelsen heraf
NO993731L (no) Pyrrolopyrazolopyrimidin-forbindelse og medisin omfattende denne
EP1124850A4 (en) 12 HUMAN SECRETED PROTEINS
ID23528A (id) Pengobatan terapeutik untuk gangguan kulit
IS5855A (is) Algínat hylki til notkunar við meðferð á heilaæxli
DK0981349T3 (da) 5-alfa-pregnan-3-beta-ol-20-on-sulfat til behandling af tumorer og CNS sygdomme
ITMI940199A0 (it) Catetere e procedimento per la sua fabbricazione
IT233164Y1 (it) Brandina o cuccia pieghegole e/o smontabile.
ID28817A (id) Penggunaan turunan-turunan tetrahidropiridin (atau4-hidropiperidin)-butilazol dalam pembuatan obat untuk perawatan nyeri
KR950022790U (ko) 의료용 침구